FDA Approves Mesoblast’s Ryoncil for Steroid-Refractory aGvHD in Children
FDA approves Ryoncil, the first mesenchymal stromal cell therapy, for steroid-refractory aGvHD in children. This offers new hope for young patients with this life-threatening complication of stem cell transplants.
FDA Approves Mesoblast’s Ryoncil for Steroid-Refractory aGvHD in Children Read More »